Article: Generex Biotechnology Announces Proposed Acquisition of Antigen Express, Inc.

Generex Biotechnology Corporation announced today an agreement in principle to acquire all of the shares of privately-owned Antigen Express, Inc. in exchange for a maximum of 2,850,000 shares of the Company's common stock. The specific number of Generex shares to be issued depends on satisfaction of certain Antigen Express performance milestones over the next 18 months. This agreement is subject to the completion of due diligence and formal documentation.

Generex previously announced an agreement in principle for a collaboration to develop SARS (Severe Acute Respiratory Syndrome) vaccines with Antigen Express. These vaccines combine the Company's proprietary ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!